BPH relief that maintains sexual function
Contributing author: Kevin C. Zorn, MD, FRCSC, FACS
BPHCANADA – Canadian Surgical Institute of Prostate, Montreal, Canada
Men diagnosed with benign prostate hyperplasia (BPH), also known as an enlarged protector, are very familiar with the related side effects of the situation, such as the urgent need to urinate, nokotouria (night urinating), others. Their quality of life has probably been significantly affected and their symptoms may worsen over time by promoting prostate development. Historically, after talking to their urologist and doing their own research, many patients are not satisfied with current central line treatment options. Whether it is a life of medication or surgery that has the potential to affect their sexual function, many men choose to continue to deal with their symptoms.
This article will examine the technological and surgical developments that make it more and more considered the real meaning of the success of BPH therapy, with an emphasis on the appearance of minimally invasive BPH (fog) surgical options that provide relief of symptoms while maintaining ejaculatory function.
“I will get relief of bphph symptoms, please, without the side effects”
In the last century, there have been extraordinary developments in the sciences and surgical techniques and therefore there are many personalized approaches to BPH treatment available to doctors and patients. In addition, there has been a recent refreshed focus on providing treatment from a holistic point of view – which means not only by looking for improved urine symptoms, but also minimizing side effects. For many men, at the top of this list of side effects are any negative effects on sexual function. In fact, maintaining ejaculation function is a priority for most men suffering from BPH choosing surgical treatment.
Historically, once BPH is diagnosed before men are presented with surgical options, medication is usually offered as an initial method of treatment. These drugs will fall into one of the following categories: A1 inhibitors, 5-alpha inhibitors, phosphodiesterase-5 inhibitors, beta-3 agonists, muscarinic receptor (MRAS) competitors and combined treatment. However, many men who prescribe these drugs do not find optimal relief, do not comply with taking a lifelong, daily medication and sometimes found on new side effects – by the drugs themselves. These categories of drugs have been associated with certain serious side effects such as cardiovascular events (orthostatic hypotension, disease and dizziness), gynecomastia, acute urine retention, urinary tract infection, hypertension, headache, ingredientBorders in pharmacology2020). They are also related to a multitude of sexual function -related side effects, including ejaculation malfunction, reduced dysfunction of libido and erectile dysfunction. In addition, they do not deal with the underlying cause of the issue – bladder obstruction.
The demand for patients has soared over the previous number of years for BPH treatments that not only provide relief of symptoms but also have no negative side effects. It is not surprising that this demand has led to the development of therapeutic options outside the drug management, including fog that does not require men to take pills for the rest of their lives and also address the real issue of bladder obstruction. But even among the new fog options, some have continued to have relevant side effects – especially related to sexual function.
Fortunately, the years since it came on stage, we have seen an ongoing development of technological progress that lead to treatment options that are even less invasive and at the end of the day, maintain ejaculation function.
Because of this, today we see the fogs increasingly considered as a first -line treatment option. Many of the available options today have a low -side risk risk profile, are made in an external patients with patients who see quick recovery hours and are safe and effective. Fog choices cleared by the American Food and Drug Administration are safe and effective include treatments such as the Optilume BPH catheter system, urethral lift (PUL), Rezum, Laquablation and Temporarily Implanted Nitinol devices.
With these new approaches, the goal is still to promote the ideal BPH treatment trifecta, which means relief of the symptoms that last while maintaining urine maintenance and sexual function.
New technologies, advanced techniques and a way of thinking
Today, more than ever, urologists have a different tool to meet the needs and desires of patients. Patients with different sizes of prostate, ages, co -hosts and individual prices have personalized BPH treatment options available to them. But the dawn of these new technologies has also played a key role in strengthening urologists to preserve ejaculation effects, as well as their understanding of basic anatomical milestones necessary for sexual maintenance. Recent pelvic imaging research during ejaculation has caused a shift from surgical emphasis on the closure of the bladder neck to maintain male ejaculation and, on the contrary, the importance of maintaining the pericic tissue surrounding Verumontanum. In addition, studies have shown that maintaining ejaculations can be achieved by approximately 90%, if it is 10 mm near Verumontanum during branch prostate resection (Turp), in combination with a 7.5 mm tissue block from the means of the Verumontan.
In addition to these technological and surgical developments, there is also a shift in thinking about the need to remove prostate tissue for the successful treatment of BPH. Traditional BPH treatment methods have included cutting, steam or excess prostate tissue, but even in recent years new options have been available that do not require prostate tissue removal and no implants left. This is important because when BPH treatments are associated with erectile or ejaculation dysfunction or backward ejaculation, it is usually due to factors such as the effect on the neck of the bladder, indirect thermal injury to the erectile nerves, injury to the interior. etc.
Conclusion
We have seen an evolution in the world of BPH management over time in a patient rich, rich in approach, where true success in treatment means relieving urine symptoms as well as maintaining the function and satisfaction of ejaculation. Today’s urologists use cutting-edge imaging technologies, using the use of advanced precision surgical techniques and remain at the top of strong, ongoing research and the available technologies that take into account anatomical thoughts so that they can give their patients what they really want to do.
About the author: Dr. Zorn
Kevin C. Zorn, MD, FACS, FRCSC, is the founder of the Canadian Canadian Surgical Institute of Canada, a personalized, private, prostate center founded in 2023 to provide all approved BPHNA treatments to Canadian men and director Robotic & Mis Prostate Prostate Prostate Prostate. Dr. Zorn is a former Associate Professor of Urology at the University of Montreal (Chum) and the University of Chicago, sub-dedication to robotic surgery and benign surgery (BPH).
Dr. Zorn attended the McGill University for the PRO-MED program, his degree and his stay in urological surgery. He became a member of the Royal College of Physicians and Surgeons of Canada (FRCSC) in 2005. Dr. Zorn also completed a two -year scholarship in Oncology and Endology at the University of Chicago. In 2007, he became a US Council of Urology was certified in urology and a member of the American College of Surgeons.
Research and innovation were the features of Dr. Zorn’s career. Among the many of his first, he was the first in Canada and Quebec to use many new BPH technologies, including Greenlight XPS, Rezum, Itind, Optilume, Aquablation and Zenflow.
Dr. Zorn is the senior author of the guidelines for the male symptoms of the lower urinary tract (Luts)/BPH for the Canadian Urological Union 2018 and 2022 (CUA) and consulted the guidelines of the American Urological Union BPH. Dr. Zorn has authored 400 publications by peer and 12 BPH book chapters and minimally invasive surgery. With such awards, Dr. Zorn has become a sought -after speaker, teacher and researcher. He has traveled to the lecture, teaching and proctor surgery around the world and is closely involved in the development of several innovative BPH technologies. In 2024, Dr. Zorn retired from his post at the University of Montreal to devote his full clinical practice to BPph Canada.
The views on this blog do not necessarily reflect the views and views of the men’s health network.
